Chew Product - Line Extension

Oxford Pharmascience Group plc("Oxford Pharmascience" or "the Company")Chew Product - Line Extension

Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, today announces that it has agreed a line extension in Brazil with its partner Aché Pharmaceuticos (Aché) for a new version of its calcium and vitamin D chew marketed under the brand name Inellare.

Sales to Aché of this new format are expected to begin in Q3 2014 for launch in Brazil later this year.

Marcelo Bravo, Chief Executive Officer of Oxford Pharmascience commented,

"The Inellare calcium and vitamin D product continues to consolidate its presence in the Brazilian market and we are working closely with our partner Ache Laboratorios to provide them with further innovative extensions to their product range. We look forward to continue building the OXPChew business in Brazil and elsewhere as opportunities arise."

For further information:

Oxford Pharmascience Group Plc

Marcelo Bravo, Chief Executive +44 20 7554 5875

N+1 Singer (Nominated Adviser & Broker)

Aubrey Powell/Jen Boorer +44 20 7496 3000

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not manufacture or sell its own pharmaceutical products direct to consumers, but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios. 

Oxford Pharmascience Group Plc focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance. By working with such medicines, the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.